Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$38.49 USD

38.49
428,011

+0.83 (2.20%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $38.45 -0.04 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

SurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SurModics (SRDX) Reports Break-Even Earnings for Q1

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 100% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More

by Debanjana Dey

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.

Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform

by Zacks Equity Research

Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.

SurModics (SRDX) Soars 6.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Shaun Pruitt headshot

2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly Results

by Shaun Pruitt

After impressive quarterly results on Wednesday, here are two highly-ranked Zacks Medical sector stocks that investors may want to consider.

Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.

SurModics (SRDX) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Vaishali Doshi headshot

Snap These 4 Top-Ranked Liquid Stocks for Solid Returns

by Vaishali Doshi

Here are four top-performing liquid stocks, Deckers Outdoor (DECK), Surmodics (SRDX), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for solid returns.

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Vaishali Doshi headshot

Add These 4 Top-Ranked Liquid Stocks to Strengthen Portfolio

by Vaishali Doshi

Here are four top-ranked liquid stocks, Surmodics (SRDX), Fluor Corporation (FLR), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for solid gains.

Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.

Vaishali Doshi headshot

Snap Up These 4 Top-Performing Liquid Stocks for Solid Gains

by Vaishali Doshi

Here are four top-ranked liquid stocks, Surmodics (SRDX), Fluor Corporation (FLR), NVIDIA (NVDA) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.

Why You Should Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Vaishali Doshi headshot

Enrich Your Portfolio With These 4 Top-Ranked Liquid Stocks

by Vaishali Doshi

Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and NVIDIA (NVDA), which investors can add to their portfolio for solid gains.

Vaishali Doshi headshot

Add These 4 Top-Performing Liquid Stocks for Strong Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.

Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.

SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 213.04% and 96.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 8.16% and 2.88%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of 55.56% and 3.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB

by Zacks Equity Research

Surmodics' (SRDX) SurVeil DCB is indicated to treat percutaneous transluminal angioplasty in peripheral artery disease patients. Abbott will initiate commercialization of SurVeil DCB, per a deal with Surmodics.